GENNEXPharmaceuticals
Gennex Laboratories Ltd — Profit & Loss Statement
₹7.13
-11.88%
Gennex Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.07 Cr | -0.11 Cr | — |
| Tax Rate For Calcs | 0.16 | 0.20 | 0.23 | 0.23 | — |
| Normalized EBITDA | 27.15 Cr | 21.94 Cr | 8.36 Cr | 7.25 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.29 Cr | -0.49 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.29 Cr | -0.49 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 18.12 Cr | 13.18 Cr | 4.92 Cr | 3.92 Cr | — |
| Reconciled Depreciation | 1.99 Cr | 2.37 Cr | 0.92 Cr | 0.79 Cr | — |
| Reconciled Cost Of Revenue | 97.08 Cr | 48.85 Cr | 40.86 Cr | 38.67 Cr | — |
| EBITDA | 27.15 Cr | 21.94 Cr | 8.65 Cr | 6.76 Cr | — |
| EBIT | 25.16 Cr | 19.57 Cr | 7.73 Cr | 5.97 Cr | — |
| Net Interest Income | -3.61 Cr | -3.08 Cr | 1.31 Cr | 0.02 Cr | — |
| Interest Expense | 3.61 Cr | 3.08 Cr | 1.35 Cr | 0.88 Cr | — |
| Normalized Income | 18.12 Cr | 13.18 Cr | 4.70 Cr | 4.30 Cr | — |
| Net Income From Continuing And Discontinued Operation | 18.12 Cr | 13.18 Cr | 4.92 Cr | 3.92 Cr | — |
| Total Expenses | 123.18 Cr | 72.05 Cr | 61.19 Cr | 56.10 Cr | — |
| Diluted Average Shares | 23.12 Cr | 21.67 Cr | 14.61 Cr | 12.65 Cr | — |
| Basic Average Shares | 22.74 Cr | 19.78 Cr | 14.61 Cr | 12.65 Cr | — |
| Diluted EPS | 0.78 | 0.61 | 0.32 | 0.31 | — |
| Basic EPS | 0.80 | 0.67 | 0.32 | 0.31 | — |
| Diluted NI Availto Com Stockholders | 18.12 Cr | 13.18 Cr | 4.92 Cr | 3.92 Cr | — |
| Net Income Common Stockholders | 18.12 Cr | 13.18 Cr | 4.92 Cr | 3.92 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 18.12 Cr | 13.18 Cr | 4.92 Cr | 3.92 Cr | — |
| Net Income Including Noncontrolling Interests | 18.12 Cr | 13.18 Cr | 4.92 Cr | 3.92 Cr | — |
| Net Income Extraordinary | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Continuous Operations | 18.12 Cr | 13.18 Cr | 4.92 Cr | 3.92 Cr | — |
| Tax Provision | 3.42 Cr | 3.32 Cr | 1.45 Cr | 1.17 Cr | — |
| Pretax Income | 21.55 Cr | 16.49 Cr | 6.37 Cr | 5.09 Cr | — |
| Other Non Operating Income Expenses | 10.43 Cr | 4.91 Cr | 0.59 Cr | 0.10 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.29 Cr | -0.49 Cr | — |
| Net Non Operating Interest Income Expense | -3.61 Cr | -3.08 Cr | 1.31 Cr | 0.02 Cr | — |
| Interest Expense Non Operating | 3.61 Cr | 3.08 Cr | 1.35 Cr | 0.88 Cr | — |
| Operating Income | 14.73 Cr | 14.66 Cr | 3.77 Cr | 5.08 Cr | — |
| Operating Expense | 26.09 Cr | 23.20 Cr | 20.33 Cr | 17.42 Cr | — |
| Other Operating Expenses | 15.75 Cr | 13.04 Cr | 8.95 Cr | 6.80 Cr | — |
| Depreciation And Amortization In Income Statement | 1.99 Cr | 2.37 Cr | 0.92 Cr | 0.79 Cr | — |
| Depreciation Income Statement | 1.99 Cr | 2.37 Cr | 0.92 Cr | 0.79 Cr | — |
| Gross Profit | 40.82 Cr | 37.86 Cr | 24.10 Cr | 22.50 Cr | — |
| Cost Of Revenue | 97.08 Cr | 48.85 Cr | 40.86 Cr | 38.67 Cr | — |
| Total Revenue | 137.90 Cr | 86.71 Cr | 64.96 Cr | 61.18 Cr | — |
| Operating Revenue | 137.90 Cr | 86.71 Cr | 64.96 Cr | 61.18 Cr | — |
| Interest Income | — | 3.79 Cr | 2.66 Cr | 0.90 Cr | 0.05 Cr |
| Rent Expense Supplemental | — | 0.10 Cr | 0.19 Cr | 0.38 Cr | 0.23 Cr |
| Other Special Charges | — | -0.58 Cr | -0.05 Cr | -34520.00 | 0.37 Cr |
| Write Off | — | -8140.00 | -0.24 Cr | 0.49 Cr | -731.00 |
| Interest Income Non Operating | — | 3.79 Cr | 2.66 Cr | 0.90 Cr | 0.05 Cr |
| Selling General And Administration | — | 2.15 Cr | 3.04 Cr | 2.52 Cr | 2.73 Cr |
| Selling And Marketing Expense | — | 1.61 Cr | 2.53 Cr | 2.13 Cr | 2.40 Cr |
| General And Administrative Expense | — | 0.54 Cr | 0.51 Cr | 0.39 Cr | 0.33 Cr |
| Rent And Landing Fees | — | 0.10 Cr | 0.19 Cr | 0.38 Cr | 0.23 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Gennex Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.